Veradermics VDPHL01: The Non-Hormonal Hair Loss Breakthrough February 2026 Update
Veradermics and the Future of Hair Growth: How VDPHL01 Compares to Emerging Therapies (2026 Update)
← View Other Hair Growth Advancements
Posted by AlviArmani | Hair Loss Innovation | Veradermics Research
The hair restoration field is entering a new era—one driven by better formulation science, stronger evidence standards, and new treatments that can be evaluated at scale. Among the leaders is the biopharmaceutical company Veradermics, whose investigational candidate VDPHL01 is an extended-release oral minoxidil tablet being studied for pattern hair loss in both men and women. Rather than introducing a brand-new molecule, VDPHL01 aims to optimize how minoxidil is delivered systemically to the hair follicle—supporting hair regrowth by smoothing exposure over time.
- Clinical trial status (men): Veradermics reported completed enrollment of 519 male subjects in a multicenter, randomized, double-blind, placebo-controlled clinical trial (often described as Phase 2/3; 52 weeks) evaluating VDPHL01 dosing including 8.5 mg once daily and 8.5 mg twice daily. This program targets male pattern baldness (androgenetic alopecia).
- Clinical trial status (women): Veradermics has described an ongoing registration-directed Phase 2/3 program for female pattern hair loss designed to enroll 500+ women in the United States.
- Endpoints & outcomes: Public sponsor communications emphasize objective measures like hair density / non-vellus hair counts plus patient-reported quality of life and hair-coverage benefit. These remain investigational until final data analysis and publication.
- How to verify: For the most current search results, see the listed trials on ClinicalTrials.gov (the public registry used for applicable clinical trials under the “drug administration amendments act” requirements—commonly referenced as the FDA Amendments Act).
Compare PP405, AMP-303, ET-02, Exosomes, 2-Deoxy-D-Ribose, VDPHL01 alongside proven options (FUE, PRP, TR6™).
Open the Hub →What Is VDPHL01?
VDPHL01 is an investigational, extended-release oral formulation of minoxidil. The goal is a steadier exposure curve that may support follicular response while minimizing sharp concentration spikes. Mechanistically, minoxidil is associated with improved scalp blood flow and follicle-level signaling that can contribute to hair regrowth; Veradermics’ strategy is primarily about delivery and tolerability, not a brand-new pathway.
This matters because the current FDA-approved prescription landscape is limited: for example, oral finasteride is commonly discussed for men, but many patients—especially women—may not be candidates. VDPHL01 is being developed as a non-hormonal option intended to generate registration-grade evidence in both sexes.
Latest Updates (Refreshed for 2026)
- Late-stage clinical studies: Sponsor communications describe multiple randomized, multicenter studies in men and women, including placebo-controlled designs, supported by a defined clinical trial design strategy.
- Preliminary data: Veradermics has referenced early signals of visible hair growth in men as early as ~2 months; these are not final clinical study results and require full trial completion and analysis.
- Regulatory path: The company has discussed late-stage development intended to support a potential New Drug Application, pending successful completion of trials and regulatory review.
Last updated: February 5, 2026
Current Trial Snapshot
VDPHL01’s program includes randomized, double-blind studies evaluating the effect of an intervention on objective hair counts and patient-reported outcomes. Trial protocols generally require participants to be in good general health, and they often include safety monitoring for blood pressure and other systemic parameters given oral dosing. These protocols also define drug administration schedules and structured study visits over many months.
- Efficacy and Safety of VDPHL01 in Males With AGA — NCT06724614
- Safety and Efficacy of VDPHL01 in Males With AGA — NCT06972264
- Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia — NCT07146022
What Eligibility Criteria Often Look Like (Patient-Friendly)
Exact inclusion criteria vary by protocol and site, but late-stage oral minoxidil trials commonly screen for cardiovascular stability and medication conflicts. For example, registries and trial explainer pages often reference exclusions such as uncontrolled blood pressure, a recent history of certain cardiovascular conditions, or current use of medications like beta blockers or systemic cimetidine. Trials may also restrict topical scalp treatments and certain dietary supplements prior to enrollment to reduce confounding.
Participants are typically monitored at scheduled study visits for vitals (including blood pressure), labs, and side effects—sometimes including tracking of weight changes. Each site’s principal investigator oversees protocol adherence and safety monitoring.
Note: Always refer to each NCT listing for the official eligibility criteria and contact details. This section is educational and not medical advice.
Trial Tracker + Practical Enrollment Notes
VDPHL01 Trial Tracker
Randomized, placebo-controlled clinical studies evaluating oral drug administration schedules and outcomes like hair density and coverage benefit.
- Identifiers: NCT06724614, NCT06972264
- Oversight: Site-level principal investigator confirms eligibility and safety procedures.
- Timing: Protocols may show different completion dates and date changes over time; always verify on the registry.
Registration-directed trial tracking outcomes in female subjects; enrollment depends on protocol-defined inclusion criteria and screening.
- Identifier: NCT07146022
- Biological sex: Registry defines the eligible population and screening rules.
- Enrollment questions: Use the NCT “Contacts and Locations” section for site contact information and additional information.
Note: Trial registries may contain administrative fields (including results delays and updates). If you see “delay results” language, it is typically a registry status field—not a clinical interpretation.
Micro-FAQ
Q: Is VDPHL01 available through compassionate use or expanded access use?
A: Expanded access policies are sponsor-specific. If Veradermics offers compassionate use / expanded access, it would be described by the sponsor; start with the NCT listing and the sponsor’s trial site for official guidance.
Q: Does this relate to finasteride side effects like erectile dysfunction?
A: VDPHL01 is being developed as a non-hormonal approach. Concerns such as erectile dysfunction are often associated with discussions around oral finasteride, which works through hormonal pathways; VDPHL01’s mechanism and safety profile are different and must be judged by its own trial results.
Q: Why do trials restrict certain meds or products?
A: Trials often restrict confounders to isolate the effect of the intervention—this can include topical scalp treatments, certain dietary supplements, and drug classes that affect vitals like blood pressure (e.g., beta blockers), per the protocol.
Quick Comparison Table (Refreshed)
| Therapy | Developer | Mechanism Focus | Stage | Notable Feature |
|---|---|---|---|---|
| VDPHL01 | Veradermics | Extended-release oral minoxidil (systemic exposure optimization) | Late-stage clinical trial program (men & women) | Non-hormonal oral approach designed to generate registration-grade evidence for hair regrowth |
| PP405 | Pelage Pharmaceuticals | Regenerative signaling (topical program, per company communications) | Clinical development (publicly described) | Short-course topical strategy targeting follicular biology |
| ET-02 | Eirion Therapeutics | Follicular + melanocyte stem cell biology (investigational) | Clinical development (publicly described) | Dual-interest: density + pigmentation pathways |
| TR6 | AlviArmani | Botanical multi-pathway scalp & follicle support | In active use | Core of AlviArmani’s integrated growth ecosystem |
Final Thoughts
Veradermics’ VDPHL01 stands out by aiming to “professionalize” a known mechanism into a purpose-built extended-release oral formulation, supported by late-stage placebo-controlled trials in both men and women. If outcomes remain favorable, this could meaningfully expand treatment options—especially for women—after full results and regulatory review.
At AlviArmani, we track promising research while delivering results through proven in-house systems like TR6 and exosome therapy. We also monitor other breakthrough candidates like PP405 and ET-02.
AlviArmani Research Institute
8500 Wilshire Blvd, Suite 1020, Beverly Hills, CA 90211
Phone: (310) 652-6444
www.alviarmani.com/research-institute/